Nikolai Naryshkin BS, MS, PhD

Dr. Naryshkin is Vice President of Biology and has been involved in discovery and development of small molecule modulators of RNA-mediated processes for over 16 years. Dr. Naryshkin’s current work is focused on discovery and development of small molecule splicing modifiers as oral therapeutics for neuromuscular disorders. Two of the most advanced programs are SMN2 splicing modifiers for treatment of spinal muscular atrophy (in collaboration with Roche and the SMA Foundation) and IKBKAP splicing modifiers for treatment of familial dysautonomia (in collaboration with the Slaugenhaupt lab at Massachusetts General Hospital). Dr. Naryshkin received his Ph.D. in bioorganic chemistry from Moscow State University in Moscow, Russia, and completed postdoctoral training in molecular biology at Rutgers University.